Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-1D
2024-511867-27-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in arterial calcification, diabetes mellitus type 1 (T1D), peripheral artery occlusion (PAD) and 1 more comparing Metformin with Placebo (2 arms). Primary endpoint: Primary. Planned start Sep 2024; status: authorised.
02
Drugs
metformin
03
Conditions
arterial calcificationdiabetes mellitus type 1 (T1D)peripheral artery occlusion (PAD)Coronary artery calcification (CAC)
Beyond the preview
Go deeper on 2024-511867-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511867-27-00.